311 related articles for article (PubMed ID: 8756081)
21. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
Xiong SL; Wang Q; Zheng L; Li JL; Wen ZB; He SL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1821-3. PubMed ID: 18158992
[TBL] [Abstract][Full Text] [Related]
22. The tissue factor pathway in disseminated intravascular coagulation.
Østerud B; Bjørklid E
Semin Thromb Hemost; 2001 Dec; 27(6):605-17. PubMed ID: 11740684
[TBL] [Abstract][Full Text] [Related]
23. [Tissue factor and tissue factor pathway inhibitor during specific bronchial challenge in allergic asthma patients].
Kemona-Chetnik I; Bodzenta-Lukaszyk A; Kucharewicz I; Rogalewska AM
Przegl Lek; 2005; 62(2):98-101. PubMed ID: 16095153
[TBL] [Abstract][Full Text] [Related]
24. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.
Langer F; Spath B; Haubold K; Holstein K; Marx G; Wierecky J; Brümmendorf TH; Dierlamm J; Bokemeyer C; Eifrig B
Ann Hematol; 2008 Jun; 87(6):451-7. PubMed ID: 18292996
[TBL] [Abstract][Full Text] [Related]
25. [Effects of tissue factor pathway inhibitor-1 on no-reflow in a rabbit model].
Luo JG; Chen YD; Tian F; Wang CH; Lü Y; Yang XX; Lü SZ
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Dec; 37(12):1113-8. PubMed ID: 20193184
[TBL] [Abstract][Full Text] [Related]
26. Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor-A in carotid atherosclerotic plaques.
Migdalski A; Kotschy M; Jawien A
Eur J Vasc Endovasc Surg; 2005 Jul; 30(1):41-7. PubMed ID: 15933981
[TBL] [Abstract][Full Text] [Related]
27. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
28. [Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation].
Fukuda C; Iijima K; Nakamura K
Rinsho Byori; 1996 Aug; 44(8):750-6. PubMed ID: 8816061
[TBL] [Abstract][Full Text] [Related]
29. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation.
Okugawa Y; Wada H; Noda T; Sakakura M; Nakasaki T; Watanabe R; Deguchi H; Gabazza EC; Mori Y; Nishikawa M; Deguchi K; Nobori T; Shiku H
Am J Hematol; 2000 Nov; 65(3):210-4. PubMed ID: 11074537
[TBL] [Abstract][Full Text] [Related]
30. [Levels of plasma TF and TFPI activities in patients with acute leukemia].
Zhu Y; Xie ZX; He XF; Han JZ; Li JC; He SL
Hunan Yi Ke Da Xue Xue Bao; 2000 Aug; 25(4):401-2, 405. PubMed ID: 12206017
[TBL] [Abstract][Full Text] [Related]
31. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
Lupu C; Kruithof EK; Kakkar VV; Lupu F
Thromb Haemost; 1999 Dec; 82(6):1652-8. PubMed ID: 10613651
[TBL] [Abstract][Full Text] [Related]
32. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients.
Wada H; Sakuragawa N; Shiku H
Semin Thromb Hemost; 1998; 24(3):293-7. PubMed ID: 9701463
[TBL] [Abstract][Full Text] [Related]
33. Tissue factor in trauma and organ dysfunction.
Gando S
Semin Thromb Hemost; 2006 Feb; 32(1):48-53. PubMed ID: 16479462
[TBL] [Abstract][Full Text] [Related]
34. Tissue factor pathway inhibitor response does not correlate with tissue factor-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients.
Gando S; Nanzaki S; Morimoto Y; Ishitani T; Kemmotsu O
Crit Care Med; 2001 Feb; 29(2):262-6. PubMed ID: 11246303
[TBL] [Abstract][Full Text] [Related]
35. The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients.
Teng Y; Jiang R; Lin Q; Ding C; Ye Z
Thromb Res; 2010 Jul; 126(1):e41-5. PubMed ID: 20226500
[TBL] [Abstract][Full Text] [Related]
36. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
37. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.
de Jonge E; van der Poll T; Kesecioglu J; Levi M
Semin Thromb Hemost; 2001 Dec; 27(6):667-74. PubMed ID: 11740690
[TBL] [Abstract][Full Text] [Related]
38. Plasma level of stromal derived factor-1 (SDF-1) is increased in disseminated intravascular coagulation patients who have poor outcomes: in vitro effect of SDF-1 on coagulopathy.
Kim HK; Kim JE; Chung J; Lee DS; Han KS; Park S; Cho HI
Thromb Res; 2007; 120(4):559-66. PubMed ID: 17239427
[TBL] [Abstract][Full Text] [Related]
39. Tissue factor pathway inhibitor: structure, biology and involvement in disease.
Lwaleed BA; Bass PS
J Pathol; 2006 Feb; 208(3):327-39. PubMed ID: 16261634
[TBL] [Abstract][Full Text] [Related]
40. Microparticles (MPs), tissue factor (TF) and tissue factor inhibitor (TFPI) in cord blood plasma. A preliminary study and literature survey of procoagulant properties of MPs.
Uszyński M; Zekanowska E; Uszyński W; Kuczyński J; Zyliński A
Eur J Obstet Gynecol Reprod Biol; 2011 Sep; 158(1):37-41. PubMed ID: 21664032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
